Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

NCT05645718 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Cyclophosphamide
DRUG: Vincristine
DRUG: Blinatumomab
DRUG: Methotrexate
DRUG: Cytarabine
DRUG: Mercaptopurine
DRUG: Prednisone
DRUG: Pegfilgrastim
DRUG: Inotuzumab ozogamicin
DRUG: Rituximab
DRUG: Dexamethasone

Sponsor

M.D. Anderson Cancer Center